Avineuro Pharmaceuticals, Inc.:製薬企業の治療薬開発パイプライン2014

【英語タイトル】Avineuro Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Global Markets Directが出版した調査資料(GMDHC06285CDB)・商品コード:GMDHC06285CDB
・発行会社(調査会社):Global Markets Direct
Single UserUSD1,500 ⇒換算¥169,500見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD4,500 ⇒換算¥508,500見積依頼/購入/質問フォーム

Avineuro Pharmaceuticals, Inc. – Product Pipeline Review – 2014


Global Markets Direct’s, ‘Avineuro Pharmaceuticals, Inc. – Product Pipeline Review – 2014’, provides an overview of the Avineuro Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Avineuro Pharmaceuticals, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides brief overview of Avineuro Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Avineuro Pharmaceuticals, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Avineuro Pharmaceuticals, Inc.’s pipeline products

Reasons to buy

- Evaluate Avineuro Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Avineuro Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Avineuro Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Avineuro Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Avineuro Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Avineuro Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues


Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Avineuro Pharmaceuticals, Inc. Snapshot 5
Avineuro Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Avineuro Pharmaceuticals, Inc. – Research and Development Overview 6
Key Therapeutic Areas 6
Avineuro Pharmaceuticals, Inc. – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
Pipeline Products – Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Avineuro Pharmaceuticals, Inc. – Pipeline Products Glance 12
Avineuro Pharmaceuticals, Inc. – Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Avineuro Pharmaceuticals, Inc. – Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Avineuro Pharmaceuticals, Inc. – Drug Profiles 15
AVN-101 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
AVN-211 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
AVN-397 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
AVN-322 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
AVN-457 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
AVN-458 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
AVN-492 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Avineuro Pharmaceuticals, Inc. – Pipeline Analysis 22
Avineuro Pharmaceuticals, Inc. – Pipeline Products by Target 22
Avineuro Pharmaceuticals, Inc. – Pipeline Products by Route of Administration 23
Avineuro Pharmaceuticals, Inc. – Pipeline Products by Molecule Type 24
Avineuro Pharmaceuticals, Inc. – Pipeline Products by Mechanism of Action 25
Avineuro Pharmaceuticals, Inc. – Recent Pipeline Updates 26
Avineuro Pharmaceuticals, Inc. – Locations And Subsidiaries 27
Head Office 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 29
Disclaimer 29



★調査レポート[Avineuro Pharmaceuticals, Inc.:製薬企業の治療薬開発パイプライン2014] (コード:GMDHC06285CDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[Avineuro Pharmaceuticals, Inc.:製薬企業の治療薬開発パイプライン2014]についてメールでお問い合わせ